1 March 2014 in Asian Pacific Journal of Cancer Prevention
Alternative Messenger RNA Splicing of Autophagic Gene Beclin 1 in Human B-cell Acute Lymphoblastic Leukemia Cells Beclin 1;alternative splicing;autophagy;acute leukemia; Beclin 1 is a key factor for initiation and regulation of autophagy, which is a cellular catabolic process involved in tumorigenesis. To investigate the role of alternative splicing of Beclin1 in the regulation of autophagy in leukemia cells, Beclin1 mRNA from 6 different types of cell lines and peripheral blood mononuclear cells from 2 healthy volunteers was reversely transcribed, subcloned, and screened for alternative splicing. New transcript variants were analyzed by DNA sequencing. A transcript variant of Beclin 1 gene carrying a deletion of exon 11, which encoded a C-terminal truncation of Beclin 1 isoform, was found. The alternative isoform was assessed by bioinformatics, immunoblotting and subcellular localization. The results showed that this variable transcript is generated by alternative 3' splicing, and its translational product displayed a reduced activity in induction of autophagy by starvation, indicating that the spliced isoform might function as a dominant negative modulator of autophagy. Our findings suggest that the alternative splicing of Beclin 1 might play important roles in leukemogenesis regulated by autophagy.
9 October 2019 in Carcinogenesis
Ecotropic viral integration site 1 (EVI1) is an oncogenic transcription factor, which is abnormally expressed in myeloid leukemia and other several solid cancers. It is associated with short survival as well as anticancer drug resistance. Autophagy is a protective mechanism that promotes cancer cell growth and survival under stressed conditions including clinical drug treatment. Here evidences are provided that EVI1 induces autophagy and mediated drug resistance in myeloid leukemia cells. Both knockdown using RNAi and pharmacological inhibition of autophagy significantly increase sensitivity to cytotoxic drug treatment in EVI1high cells. Mechanistic studies revealed that EVI1 regulated autophagy by directly binding to autophagy-related gene autophagy related 7 (ATG7) promoter and transcriptionally upregulating its expression. Notably, ATG7 expression was positively correlated with EVI1 in bone marrow mononuclear cells from myeloid leukemia patients. Acute myeloid leukemia patients with high level of EVI1 are associated with unfavorable overall survival, which was aggravated by simultaneous high expression of ATG7 in these patients. Furthermore, ChIP and firefly luciferase reporter assay identified an EVI1-binding site at 227 upstream promoter region of ATG7 which regulated its transcription. In addition, enforced expression of EVI1 also increased intracellular reactive oxygen species and ATG7 mRNA levels as well as autophagy activity, whereas the increase was attenuated after treatment with reactive oxygen species scavenger, suggesting the involvement of reactive oxygen species in EVI1-induced autophagy. These findings demonstrate that EVI protects myeloid leukemia cell from anticancer drug treatment by inducing autophagy through dual control of ATG7. These results might present a new therapeutic approach for improving treatment outcome in myelogenous leukemia with EVI1high.
25 October 2018 in Pathology and Oncology Research
Although the implication of BCL3 has been disclosed in human chronic lymphocytic leukemia as well as other solid tumors, the diagnostic and prognostic of BCL3 expression in acute myeloid leukemia (AML) remains largely unclear. In this study, we isolated total RNA from bone marrow mononuclear cells collected from 101 de novo AML patients and 27 healthy donors. After reverse transcription, quantitative real-time PCR was performed to detect BCL3 expression level. BCL3 mRNA level was significantly down-regulated in BMMCs of AML patients compared with healthy controls (P = 0.0015). BCL3 was showed a higher level in AML patients with poor-risk karyotypes than that of in patients with favorable/intermediate-risk karyotypes (P = 0.014). ROC analysis demonstrated that BCL3 could effectively differentiate AML patients from normal controls. Among the French-American-British (FAB) subtypes, the frequency of low BCL3 expression in M2 subtypes is significantly higher than that of in the other subtypes M1/M4/M5/M6/M7 (P = 0.006), and mildly lower in myelomonocytic/monocytic subtypes M4/M5 (P = 0.064) than those in M1/M2/M6/M7 subtypes. Chromosome analysis revealed that BCL3low patients had a remarkably higher frequency of t (8;21) abnormality (P = 0.0047) and lower frequency of normal karyotype (P = 0.0059) than BCL3high patients. BCL3high patients showed a significantly higher frequency of FLT3-ITD mutation (P = 0.028) and lower frequency of C-Kit mutation (P = 0.0232) than BCL3low patients. Although there were no significant differences in complete remission and overall survival between BCL3low and BCL3high groups, patients with high BCL3 expression markedly shorter overall survival (OS, P = 0.049), relapse-free survival (RFS, P = 0.027) and disease-free survival (DFS, P = 0.042) in M2 AML than low BCL3 expression patients. Additionally, in AMLs of M2 subtype, high BCL3 expression patients had markedly lower complete remission (CR) rate (P = 0.0317) after the second induction treatment than patients with BCL3 low expression. Thus, these findings indicated that BCL3 appeared as a promising molecular biomarker of pediatric acute myeloid leukemia with unfavorable prognosis.
10 February 2026 in Immunobiology
The progression of esophageal cancer is closely linked to the establishment of an immunosuppressive tumor microenvironment. Although B-cell leukemia/lymphoma 3 (BCL3) is dysregulated in various cancers, its specific role and mechanism in shaping the immune microenvironment of esophageal cancer, particularly in macrophage polarization, remain elusive. BCL3 was significantly overexpressed in esophageal cancer tissues, demonstrated good diagnostic value (AUC = 0.75, P < 0.01), and its high expression was significantly associated with poor patient prognosis (P < 0.05). Immune infiltration analysis revealed that high BCL3 expression correlated with increased M2 macrophage infiltration. In vitro experiments confirmed that knocking down BCL3 suppressed M2 macrophage polarization. Mechanistic studies indicated that BCL3 drives M2 polarization by enhancing the phosphorylation of STAT3. Our study unveils a novel mechanism whereby BCL3 promotes an immunosuppressive tumor microenvironment in esophageal cancer by facilitating M2 macrophage polarization via the STAT3 signaling pathway. BCL3 represents a potential prognostic biomarker and a promising therapeutic target for immunotherapy in esophageal cancer.
23 February 2026 in SSRN Electronic Journal
Background Gout is a significant risk factor for severe COVID-19 and associated mortality. Anti-gout therapeutics such as colchicine have shown efficacy against COVID-19, suggesting shared pathological mechanisms. However, the underlying molecular connections between gout and severe COVID-19 remain unclear.,Methods We performed an integrated bioinformatic analysis using transcriptomic datasets from gout (GSE160170) and severe COVID-19 (GSE171110) to identify common differentially expressed genes (DEGs). Functional enrichment, protein-protein interaction (PPI) network analysis, and hub gene identification were conducted. Molecular docking and 100 ns molecular dynamics simulations were used to evaluate the binding between colchicine and the candidate target protein. Additionally, candidate small-molecule drugs and herbal formulas were screened based on hub genes.,Results We identified 19 common DEGs enriched in immune-related pathways. Six hub genes (CXCL8, MPO, JUN, MMP1, IL4, IL10) were identified, among which MMP1 was the only gene overlapping with colchicine's predicted targets. Molecular docking revealed stable binding between colchicine and MMP1, with a binding affinity of -6.4 kcal/mol. Molecular dynamics simulations confirmed the stability of the colchicine-MMP1 complex based on RMSD, RMSF, Rg, and hydrogen bonding analyses. Ten candidate small-molecule drugs and six herbal formulas targeting the hub genes were proposed. Single-cell RNA sequencing further validated elevated MMP1 expression in B cells of severe COVID-19 patients.,Conclusion Our study identifies MMP1 as a shared therapeutic target for gout and severe COVID-19 and provides novel mechanistic insight into colchicine's anti-inflammatory action via direct interaction with MMP1. These findings offer a resource for understanding the comorbidity and may inform the development of new treatment strategies.